Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
hydroxyurea
myeloproliferative neoplasms
polycythemia vera
ruxolitinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
received:
21
06
2023
revised:
14
07
2023
accepted:
19
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), the predictors of response, and patients' triggers for switching to ruxolitinib are uncertain. In a real-world analysis, we evaluated the predictors of response, their impact on the clinical outcomes of CR to HU, and the correlations between partial or no response (PR/NR) and a patient switching to ruxolitinib. Among 563 PV patients receiving HU for ≥12 months, 166 (29.5%) achieved CR, 264 achieved PR, and 133 achieved NR. In a multivariate analysis, the absence of splenomegaly (
Identifiants
pubmed: 37509367
pii: cancers15143706
doi: 10.3390/cancers15143706
pmc: PMC10377857
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : RC-2022-2773402
Références
J Clin Oncol. 2016 Jan 10;34(2):151-9
pubmed: 26598745
Br J Haematol. 2016 Mar;172(5):786-93
pubmed: 26898196
J Clin Oncol. 2023 Jul 1;41(19):3534-3544
pubmed: 37126762
Am J Hematol. 2012 May;87(5):552-4
pubmed: 22473827
Br J Haematol. 2010 Mar;148(6):961-3
pubmed: 19930182
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9
pubmed: 27431664
Blood. 2009 May 14;113(20):4829-33
pubmed: 19278953
Hemasphere. 2022 May 11;6(6):e721
pubmed: 35747843
Leukemia. 2021 Dec;35(12):3339-3351
pubmed: 34480106
Thrombosis. 2011;2011:794240
pubmed: 22084668
Int J Epidemiol. 2015 Dec;44(6):1800-13
pubmed: 26705418
Lancet Haematol. 2020 Mar;7(3):e226-e237
pubmed: 31982039
Blood. 2012 Feb 9;119(6):1363-9
pubmed: 22160617
Lancet Haematol. 2022 Apr;9(4):e301-e311
pubmed: 35358444
Haematologica. 2005 Feb;90(2):261-2
pubmed: 15710584
Haematologica. 2017 Jan;102(1):18-29
pubmed: 27884974
Ann Hematol. 2018 Sep;97(9):1591-1600
pubmed: 29804268
Lancet Haematol. 2022 Jul;9(7):e480-e492
pubmed: 35597252
Leukemia. 2008 Feb;22(2):437-8
pubmed: 17728787
Lancet Oncol. 2017 Jan;18(1):88-99
pubmed: 27916398
Blood. 2013 Jun 6;121(23):4778-81
pubmed: 23591792
Blood. 2020 May 7;135(19):1696-1703
pubmed: 32107559
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
J Clin Oncol. 2005 Apr 1;23(10):2224-32
pubmed: 15710945